News & Updates

In the longer-term follow-up of the phase III AUGMENT trial, the lenalidomide-rituximab (R2) combination trumped the rituximab-placebo regimen (control) for the treatment of relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).

Exposure to dihydropyridine calcium channel blockers does not appear to put patients at increased risk of developing pancreatic cancer as compared with thiazide diuretics, as shown in a large study.

Discontinuation of renin-angiotensin system inhibitors (RASIs) is associated with higher risks of cardiorenal complications and neutral risk of all-cause mortality in patients with type 2 diabetes (T2D) and advanced chronic kidney disease (CKD), according to researchers from the Chinese University of Hong Kong (CUHK).

Researchers at the Chinese University of Hong Kong (CUHK) are recruiting pregnant women with inflammatory bowel disease (IBD), their newborns and spouse for a study to investigate how early-life exposure influences gut microbiota and IBD risk in the offspring, and to develop novel treatments for the increasingly prevalent condition.

Rapidly maximizing medications in patients discharged from hospital following acute heart failure (AHF) reduced the risk of hospital readmission or death at 180 days, according to results of the STRONG-HF* trial presented at AHA 2022.

Local-control outcomes are encouraging in patients with osseous renal cell carcinoma metastases who went through five fractions of stereotactic body radiotherapy (SBRT), reports a study.

Anti-inflammatory dietary patterns, such as the Mediterranean diet, may improve the chances of conception among couples who struggle with infertility, according to a recent review.

In a study presented at ASH 2022, obesity was found to be associated with adverse outcomes in individuals with primary immune thrombocytopenia (ITP; formerly known as thrombocytopenia purpura).